Sign in
Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety and Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2018
Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial
Rishi P. Singh, MD
SCORE2 Month 6 to Month 12 Results: 12 Month Outcomes of Treatment Change among Poor Responders at Month 6
Michael S. Ip, MD
Category: Instrumentation and Devices